• LinkedIn
Please select your page

Investor Relations

We are a biopharmaceutical company focused on the discovery and development of products to prevent and treat serious and potentially life-threatening viral respiratory infectious diseases.

The Company currently has two Phase 2 clinical-stage product candidates: (i) laninamivir octanoate, which is being developed for the treatment of influenza A and B infections and (ii) vapendavir, a potent, broad spectrum capsid inhibitor of enteroviruses, including human rhinovirus (HRV), which is being developed to treat patients with underlying respiratory illnesses, such as asthma and chronic obstructive pulmonary disease, that are infected with HRV. In addition to these clinical development programs, the Company also has a compound BTA-C585, a fusion inhibitor, in IND-enabling studies for the treatment of respiratory syncytial virus infections.

In addition to our research and development activities, we receive royalty revenue from two approved neuraminidase inhibitors: zanamivir, marketed worldwide as Relenza® by GlaxoSmithKline; and LANI, marketed in Japan as Inavir® by Daiichi-Sankyo.


 

NASDAQ: BOTA
2.46
- 0.01 (--0.41%)
4:00 PM ET on Oct 22, 2014
Delayed at least 20 minutes.